When David Martinez started feeling exhausted last spring, his doctor ordered a scan. Then another. Then a biopsy. Five months later, he had his diagnosis: stage III lymphoma. By then, it had spread. His oncologist later asked a question that standard diagnostic medicine rarely asks in time: could this have been caught earlier?
Harbinger Health, a Flagship Pioneering startup that launched in 2020, has raised $100 million to answer that question with a blood test. According to the company's announcement, RESOLVE is designed for exactly the space Martinez occupied: the weeks and months between when symptoms first appear and when a pathologist can say the word "cancer" with certainty. The company says faster answers save lives, that mortality increases up to 8% for every month of diagnostic delay, and that its test can close that gap.
The data tells a more complicated story.
At 98.3% specificity, RESOLVE generates very few false alarms: the test almost never says cancer is present when it is not. That sounds like exactly what you want. But specificity is only half the equation. At that threshold, the test catches about half of all cancers in people without an existing US screening program. For early-stage disease, the number drops to 25.8%. Late-stage cancers are detected at a much higher rate: 80.3%.
The other number that matters: when the test finds cancer, it correctly identifies the tissue of origin about 36% of the time. That means in roughly two out of three positive cases, a physician gets confirmation of a malignancy without knowing where to look for it. Harbinger argues this is acceptable because a doctor ordering the test wants to know whether cancer is present before worrying about where it started. But a patient who tests positive and then waits weeks for an imaging workup to find the actual tumor has not received a faster answer. They have received a more complicated one.
The clinical logic Harbinger is selling depends on an assumption the evidence has not fully tested: that finding cancer earlier in symptomatic patients, even with these performance characteristics, leads to better outcomes than standard diagnostic pathways. The American Cancer Society says it is not yet known whether MCD testing reduces the number of deaths caused by cancer in this population. Harbinger says its PROCARES study, currently enrolling more than 88% of its target, will help answer that question.
Flagship has now invested approximately $190 million in Harbinger across multiple rounds, the most recent being this $100 million financing. The firm does not make small bets on categories it does not believe will define the next decade of medicine. Whether RESOLVE defines it depends entirely on what PROCARES shows when it reads out. The test is real. The science is real. Whether it helps the patients who need it most is still an open question and the answer will determine whether this $100 million investment becomes a diagnostic turning point or an expensive way to tell someone they might have cancer without being able to tell them where.
